Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Finished Goods (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Finished Goods for 14 consecutive years, with $9.4 million as the latest value for Q4 2025.

  • Quarterly Finished Goods rose 14.7% to $9.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.4 million through Dec 2025, up 14.7% year-over-year, with the annual reading at $9.4 million for FY2025, 14.7% up from the prior year.
  • Finished Goods hit $9.4 million in Q4 2025 for Corcept Therapeutics, up from $8.6 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $9.4 million in Q4 2025 to a low of $4.9 million in Q3 2021.
  • Historically, Finished Goods has averaged $7.3 million across 5 years, with a median of $7.6 million in 2023.
  • Biggest five-year swings in Finished Goods: fell 25.09% in 2021 and later skyrocketed 48.95% in 2023.
  • Year by year, Finished Goods stood at $6.5 million in 2021, then surged by 41.6% to $9.2 million in 2022, then dropped by 15.9% to $7.7 million in 2023, then grew by 6.01% to $8.2 million in 2024, then rose by 14.7% to $9.4 million in 2025.
  • Business Quant data shows Finished Goods for CORT at $9.4 million in Q4 2025, $8.6 million in Q3 2025, and $6.7 million in Q2 2025.